VERTEX PHARMACEUTICALS INC / MA Insider Trading for October 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for October 2014.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 35.64 | 4,400 | 156,816 | 586,800 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 17.16 | 1,300 | 22,308 | 48,600 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 10.41 | 4,800 | 49,968 | 62,588 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 110.47 | 100 | 11,047 | 338,895 | 339 K to 338.9 K (-0.03 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 109.79 | 6,500 | 713,635 | 338,995 | 345.5 K to 339 K (-1.88 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 108.82 | 3,900 | 424,398 | 345,495 | 349.4 K to 345.5 K (-1.12 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 35.64 | 4,400 | 156,816 | 349,395 | 345 K to 349.4 K (+1.28 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 17.16 | 1,300 | 22,308 | 344,995 | 343.7 K to 345 K (+0.38 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 10.41 | 4,800 | 49,968 | 343,695 | 338.9 K to 343.7 K (+1.42 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 73.51 | 3,438 | 252,727 | 48,126 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 115.00 | 3,438 | 395,370 | 9,500 | 12.9 K to 9.5 K (-26.57 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 73.51 | 3,438 | 252,727 | 12,938 | 9.5 K to 12.9 K (+36.19 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Option Exercise | M | 63.14 | 2,000 | 126,280 | 16,000 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 114.75 | 2,000 | 229,500 | 0 | 2 K to 0 (-100.00 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Buy | M | 63.14 | 2,000 | 126,280 | 2,000 | 0 to 2 K |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Policy, Access ... | Option Exercise | M | 39.05 | 12,000 | 468,600 | 29,375 | |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Policy, Access ... | Sell | S | 115.00 | 12,000 | 1,380,000 | 38,671 | 50.7 K to 38.7 K (-23.68 %) |
Oct 30 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Policy, Access ... | Buy | M | 39.05 | 12,000 | 468,600 | 50,671 | 38.7 K to 50.7 K (+31.03 %) |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 48.74 | 1,125 | 54,833 | 7,875 | |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 111.21 | 287 | 31,917 | 17,000 | 17.3 K to 17 K (-1.66 %) |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 110.60 | 229 | 25,327 | 17,287 | 17.5 K to 17.3 K (-1.31 %) |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 109.43 | 490 | 53,621 | 17,516 | 18 K to 17.5 K (-2.72 %) |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 108.54 | 119 | 12,916 | 18,006 | 18.1 K to 18 K (-0.66 %) |
Oct 29 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 48.74 | 1,125 | 54,833 | 18,125 | 17 K to 18.1 K (+6.62 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 35.64 | 4,400 | 156,816 | 591,200 | |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 17.16 | 1,300 | 22,308 | 49,900 | |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 10.41 | 4,800 | 49,968 | 67,388 | |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 109.82 | 700 | 76,874 | 338,895 | 339.6 K to 338.9 K (-0.21 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 108.87 | 2,800 | 304,836 | 339,595 | 342.4 K to 339.6 K (-0.82 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 107.49 | 1,600 | 171,984 | 342,395 | 344 K to 342.4 K (-0.47 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 106.83 | 5,400 | 576,882 | 343,995 | 349.4 K to 344 K (-1.55 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 35.64 | 4,400 | 156,816 | 349,395 | 345 K to 349.4 K (+1.28 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 17.16 | 1,300 | 22,308 | 344,995 | 343.7 K to 345 K (+0.38 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 10.41 | 4,800 | 49,968 | 343,695 | 338.9 K to 343.7 K (+1.42 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | Riley Wayne Joseph | Director | Option Exercise | M | 53.85 | 10,000 | 538,500 | 10,000 | |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | Riley Wayne Joseph | Director | Sell | S | 110.00 | 10,000 | 1,100,000 | 400 | 10.4 K to 400 (-96.15 %) |
Oct 23 2014 | VRTX | VERTEX PHARMACEUTI ... | Riley Wayne Joseph | Director | Buy | M | 53.85 | 10,000 | 538,500 | 10,400 | 400 to 10.4 K (+2,500.00 %) |
Oct 09 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 73.51 | 3,436 | 252,580 | 51,564 | |
Oct 09 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 105.36 | 400 | 42,144 | 9,500 | 9.9 K to 9.5 K (-4.04 %) |
Oct 09 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 104.31 | 2,134 | 222,598 | 9,900 | 12 K to 9.9 K (-17.73 %) |
Oct 09 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 103.64 | 902 | 93,483 | 12,034 | 12.9 K to 12 K (-6.97 %) |
Oct 09 2014 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 73.51 | 3,436 | 252,580 | 12,936 | 9.5 K to 12.9 K (+36.17 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 35.64 | 4,400 | 156,816 | 595,600 | |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 17.16 | 1,300 | 22,308 | 51,200 | |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 102.87 | 430 | 44,234 | 338,895 | 339.3 K to 338.9 K (-0.13 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 102.27 | 2,770 | 283,288 | 339,325 | 342.1 K to 339.3 K (-0.81 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 100.84 | 1,500 | 151,260 | 342,095 | 343.6 K to 342.1 K (-0.44 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 99.85 | 900 | 89,865 | 343,595 | 344.5 K to 343.6 K (-0.26 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 97.48 | 100 | 9,748 | 344,495 | 344.6 K to 344.5 K (-0.03 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 35.64 | 4,400 | 156,816 | 344,595 | 340.2 K to 344.6 K (+1.29 %) |
Oct 17 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 17.16 | 1,300 | 22,308 | 340,195 | 338.9 K to 340.2 K (+0.38 %) |
Oct 15 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 51.75 | 1,125 | 58,219 | 3,375 | |
Oct 15 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 108.67 | 173 | 18,800 | 17,000 | 17.2 K to 17 K (-1.01 %) |
Oct 15 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 107.97 | 770 | 83,137 | 17,173 | 17.9 K to 17.2 K (-4.29 %) |
Oct 15 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 106.80 | 182 | 19,438 | 17,943 | 18.1 K to 17.9 K (-1.00 %) |
Oct 15 2014 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 51.75 | 1,125 | 58,219 | 18,125 | 17 K to 18.1 K (+6.62 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Option Exercise | M | 34.32 | 5,000 | 171,600 | 5,000 | |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 111.57 | 100 | 11,157 | 5,265 | 5.4 K to 5.3 K (-1.86 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 110.45 | 100 | 11,045 | 5,365 | 5.5 K to 5.4 K (-1.83 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 109.30 | 300 | 32,790 | 5,465 | 5.8 K to 5.5 K (-5.20 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 108.32 | 1,100 | 119,152 | 5,765 | 6.9 K to 5.8 K (-16.02 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 107.48 | 2,592 | 278,588 | 6,865 | 9.5 K to 6.9 K (-27.41 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Sell | S | 106.42 | 808 | 85,987 | 9,457 | 10.3 K to 9.5 K (-7.87 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ULLIAN ELAINE | Director | Buy | M | 34.32 | 5,000 | 171,600 | 10,265 | 5.3 K to 10.3 K (+94.97 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 111.52 | 100 | 11,152 | 42,264 | 42.4 K to 42.3 K (-0.24 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 110.37 | 400 | 44,148 | 42,364 | 42.8 K to 42.4 K (-0.94 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 109.19 | 900 | 98,271 | 42,764 | 43.7 K to 42.8 K (-2.06 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 108.08 | 4,037 | 436,319 | 43,664 | 47.7 K to 43.7 K (-8.46 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 107.32 | 5,373 | 576,630 | 47,701 | 53.1 K to 47.7 K (-10.12 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 106.32 | 1,607 | 170,856 | 53,074 | 54.7 K to 53.1 K (-2.94 %) |
Oct 08 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Option Exercise | M | 63.14 | 1,405 | 88,712 | 18,000 | |
Oct 08 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 109.75 | 1,405 | 154,199 | 0 | 1.4 K to 0 (-100.00 %) |
Oct 08 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Buy | M | 63.14 | 1,405 | 88,712 | 1,405 | 0 to 1.4 K |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Option Exercise | M | 63.14 | 10,595 | 668,968 | 19,405 | |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 112.06 | 100 | 11,206 | 0 | 100 to 0 (-100.00 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 110.48 | 300 | 33,144 | 100 | 400 to 100 (-75.00 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 109.51 | 695 | 76,109 | 400 | 1.1 K to 400 (-63.47 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 108.31 | 2,177 | 235,791 | 1,095 | 3.3 K to 1.1 K (-66.53 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 107.56 | 4,942 | 531,562 | 3,272 | 8.2 K to 3.3 K (-60.17 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Sell | S | 106.56 | 2,381 | 253,719 | 8,214 | 10.6 K to 8.2 K (-22.47 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | Director | Buy | M | 63.14 | 10,595 | 668,968 | 10,595 | 0 to 10.6 K |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Option Exercise | M | 11.27 | 5,700 | 64,239 | 0 | |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 110.00 | 100 | 11,000 | 338,895 | 339 K to 338.9 K (-0.03 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 109.21 | 300 | 32,763 | 338,995 | 339.3 K to 339 K (-0.09 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 108.02 | 1,700 | 183,634 | 339,295 | 341 K to 339.3 K (-0.50 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 107.12 | 2,400 | 257,088 | 340,995 | 343.4 K to 341 K (-0.70 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Sell | S | 105.87 | 1,200 | 127,044 | 343,395 | 344.6 K to 343.4 K (-0.35 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | BOGER JOSHUA S | Director | Buy | M | 11.27 | 5,700 | 64,239 | 344,595 | 338.9 K to 344.6 K (+1.68 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 111.52 | 100 | 11,152 | 14,895 | 15 K to 14.9 K (-0.67 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 108.30 | 200 | 21,660 | 14,995 | 15.2 K to 15 K (-1.32 %) |
Oct 03 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 107.28 | 450 | 48,276 | 15,195 | 15.6 K to 15.2 K (-2.88 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Option Exercise | M | 55.83 | 36,000 | 2,009,880 | 36,000 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Sell | S | 113.91 | 7,400 | 842,934 | 32,463 | 39.9 K to 32.5 K (-18.56 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Sell | S | 113.10 | 9,601 | 1,085,873 | 39,863 | 49.5 K to 39.9 K (-19.41 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Sell | S | 112.22 | 14,286 | 1,603,175 | 49,464 | 63.8 K to 49.5 K (-22.41 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Sell | S | 111.33 | 4,713 | 524,698 | 63,750 | 68.5 K to 63.8 K (-6.88 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Horton Kenneth L | EVP & Chief Legal O ... | Buy | M | 55.83 | 36,000 | 2,009,880 | 68,463 | 32.5 K to 68.5 K (+110.90 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | M | 29.98 | 200,000 | 5,996,000 | 213,108 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 113.90 | 41,704 | 4,750,086 | 144,992 | 186.7 K to 145 K (-22.34 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 113.10 | 53,750 | 6,079,125 | 186,696 | 240.4 K to 186.7 K (-22.35 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 112.21 | 79,817 | 8,956,266 | 240,446 | 320.3 K to 240.4 K (-24.92 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 111.31 | 24,729 | 2,752,585 | 320,263 | 345 K to 320.3 K (-7.17 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Buy | M | 29.98 | 200,000 | 5,996,000 | 344,992 | 145 K to 345 K (+137.94 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 77.31 | 6,875 | 531,506 | 48,125 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 83.36 | 6,875 | 573,100 | 20,625 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 45.11 | 17,157 | 773,952 | 28,593 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 48.74 | 15,250 | 743,285 | 15,250 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 37.86 | 3,532 | 133,722 | 4,218 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 51.75 | 5,625 | 291,094 | 1,875 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Option Exercise | M | 38.80 | 1,172 | 45,474 | 2,344 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Sell | S | 113.90 | 11,629 | 1,324,543 | 23,350 | 35 K to 23.4 K (-33.25 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Sell | S | 113.08 | 15,400 | 1,741,432 | 34,979 | 50.4 K to 35 K (-30.57 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Sell | S | 112.21 | 21,881 | 2,455,267 | 50,379 | 72.3 K to 50.4 K (-30.28 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Sell | S | 111.32 | 7,576 | 843,360 | 72,260 | 79.8 K to 72.3 K (-9.49 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 77.31 | 6,875 | 531,506 | 79,836 | 73 K to 79.8 K (+9.42 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 83.36 | 6,875 | 573,100 | 72,961 | 66.1 K to 73 K (+10.40 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 45.11 | 17,157 | 773,952 | 66,086 | 48.9 K to 66.1 K (+35.07 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 48.74 | 15,250 | 743,285 | 48,929 | 33.7 K to 48.9 K (+45.28 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 37.86 | 3,532 | 133,722 | 33,679 | 30.1 K to 33.7 K (+11.72 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 51.75 | 5,625 | 291,094 | 30,147 | 24.5 K to 30.1 K (+22.94 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Pace Megan E | SVP, Corp. Communic ... | Buy | M | 38.80 | 1,172 | 45,474 | 24,522 | 23.4 K to 24.5 K (+5.02 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | M | 37.86 | 28,594 | 1,082,569 | 17,156 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | M | 38.80 | 40,031 | 1,553,203 | 5,719 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | M | 33.82 | 10,500 | 355,110 | 0 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | M | 39.05 | 4,375 | 170,844 | 41,375 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Option Exercise | M | 33.28 | 2,500 | 83,200 | 0 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Sell | S | 113.91 | 17,247 | 1,964,606 | 38,671 | 55.9 K to 38.7 K (-30.84 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Sell | S | 113.13 | 22,646 | 2,561,942 | 55,918 | 78.6 K to 55.9 K (-28.82 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Sell | S | 112.22 | 34,753 | 3,899,982 | 78,564 | 113.3 K to 78.6 K (-30.67 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Sell | S | 111.33 | 11,354 | 1,264,041 | 113,317 | 124.7 K to 113.3 K (-9.11 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Buy | M | 37.86 | 28,594 | 1,082,569 | 124,671 | 96.1 K to 124.7 K (+29.76 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Buy | M | 38.80 | 40,031 | 1,553,203 | 96,077 | 56 K to 96.1 K (+71.43 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Buy | M | 33.82 | 10,500 | 355,110 | 56,046 | 45.5 K to 56 K (+23.05 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Buy | M | 39.05 | 4,375 | 170,844 | 45,546 | 41.2 K to 45.5 K (+10.63 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | SVP, Global Gov. St ... | Buy | M | 33.28 | 2,500 | 83,200 | 41,171 | 38.7 K to 41.2 K (+6.46 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 45.11 | 16,992 | 766,509 | 37,383 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 48.74 | 18,126 | 883,461 | 18,124 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 37.86 | 16,993 | 643,355 | 23,789 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 51.75 | 11,330 | 586,328 | 9,062 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 38.80 | 16,993 | 659,328 | 10,195 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 33.82 | 11,329 | 383,147 | 0 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 39.05 | 13,594 | 530,846 | 0 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Option Exercise | M | 33.28 | 2,267 | 75,446 | 0 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Sell | S | 113.90 | 22,156 | 2,523,568 | 44,868 | 67 K to 44.9 K (-33.06 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Sell | S | 113.10 | 28,751 | 3,251,738 | 67,024 | 95.8 K to 67 K (-30.02 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Sell | S | 112.21 | 43,112 | 4,837,598 | 95,775 | 138.9 K to 95.8 K (-31.04 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Sell | S | 111.31 | 14,007 | 1,559,119 | 138,887 | 152.9 K to 138.9 K (-9.16 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 45.11 | 16,992 | 766,509 | 152,894 | 135.9 K to 152.9 K (+12.50 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 48.74 | 18,126 | 883,461 | 135,902 | 117.8 K to 135.9 K (+15.39 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 37.86 | 16,993 | 643,355 | 117,776 | 100.8 K to 117.8 K (+16.86 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 51.75 | 11,330 | 586,328 | 100,783 | 89.5 K to 100.8 K (+12.67 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 38.80 | 16,993 | 659,328 | 89,453 | 72.5 K to 89.5 K (+23.45 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 33.82 | 11,329 | 383,147 | 72,460 | 61.1 K to 72.5 K (+18.53 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 39.05 | 13,594 | 530,846 | 61,131 | 47.5 K to 61.1 K (+28.60 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP & CFO | Buy | M | 33.28 | 2,267 | 75,446 | 47,537 | 45.3 K to 47.5 K (+5.01 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | M | 77.31 | 7,844 | 606,420 | 54,906 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | M | 83.36 | 1,500 | 125,040 | 4,500 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | M | 45.11 | 1,875 | 84,581 | 9,375 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Option Exercise | M | 53.74 | 2,813 | 151,171 | 7,500 | |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 113.89 | 3,000 | 341,670 | 15,645 | 18.6 K to 15.6 K (-16.09 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 113.03 | 4,071 | 460,145 | 18,645 | 22.7 K to 18.6 K (-17.92 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 112.18 | 5,300 | 594,554 | 22,716 | 28 K to 22.7 K (-18.92 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Sell | S | 111.29 | 1,800 | 200,322 | 28,016 | 29.8 K to 28 K (-6.04 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Buy | M | 77.31 | 7,844 | 606,420 | 29,816 | 22 K to 29.8 K (+35.70 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Buy | M | 83.36 | 1,500 | 125,040 | 21,972 | 20.5 K to 22 K (+7.33 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Buy | M | 45.11 | 1,875 | 84,581 | 20,472 | 18.6 K to 20.5 K (+10.08 %) |
Oct 01 2014 | VRTX | VERTEX PHARMACEUTI ... | Connolly Thomas | SVP, Human Resource ... | Buy | M | 53.74 | 2,813 | 151,171 | 18,597 | 15.8 K to 18.6 K (+17.82 %) |